

# Optimising the Personalisation of GU Cancer Care

Friday 13 September 2024, 18:00–19:30 CEST

Santander Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain

## Chaired by:



**Prof. Alison Birtle**  
Rosemere Cancer Centre,  
Lancashire Teaching  
Hospitals, Preston, UK



**Dr. Patrizia Giannatempo**  
Foundation IRCCS National  
Cancer Institute, Milan, Italy

## Speakers:



**Dr. Alejo Rodríguez-Vida**  
Hospital de Mar,  
Barcelona, Spain



**Dr. Elena Verzoni**  
Istituto Nazionale dei  
Tumori, Milan, Italy



**Prof. Simon Crabb**  
University Hospital,  
Southampton, UK



**Dr. Viktor Grünwald**  
University Hospital,  
Essen, Germany

## Learning Objectives:

- To understand the data-driven insights on personalisation and sequencing approaches
- To discuss the value of testing for patient outcomes
- How to balance safety, quality of life and treatment efficacy

## Agenda:

Time (CEST)	Session title	Speaker
18:00–18:10	<b>Welcome and introduction</b>	Dr. Patrizia Giannatempo (Italy) Prof. Alison Birtle (UK)
18:10–18:18	<b>Prostate cancer topics</b>	Unveiling real-world evidence: Exploring the PSA response in mHSPC
18:18–18:26		Efficacy and QoL in mHSPC – finding the right balance
18:26–18:34		The significance of BRCA1/2 mutations in mCRPC outcomes
18:34–18:47		Panel discussion
18:47–18:59	<b>Bladder cancer topics</b>	The evolving patient pathway in mUC: What do the changing guidelines mean for treatment sequencing?
18:59–19:11		FGFR testing: Why, how, when?
19:11–19:24		Optimising patient care: Managing adverse events
19:24–19:30	<b>Summary and close</b>	Dr. Patrizia Giannatempo (Italy) Prof. Alison Birtle (UK)

We look forward to seeing you there

This industry symposium is funded and organised by Johnson & Johnson in EMEA and is intended for healthcare professionals only. Janssen Pharmaceutica NV, a Johnson & Johnson company, Turnhoutseweg 30, B-2340 Beerse, Belgium.

BRCA, breast cancer gene; FGFR, fibroblast growth factor receptor; GU, genitourinary; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; mUC, metastatic urothelial carcinoma; PSA, prostate-specific antigen; QoL, quality of life.

EM-159259 | August 2024